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Two reports in this issue of the Journal 
of Investigative Dermatology shed light 
on possible mechanisms of action of 
fumarate esters. Meissner et al. (2011) 
demonstrate that dimethylfumarate 
causes a decrease in tube formation 
in human endothelial cells in vitro. 
Analysis of angiogenic factors in 
endothelial cells treated with dimethyl-
fumarate revealed a decrease in vascu-
lar endothelial growth factor receptor 
2 (VEGFR2) protein but not in VEGFR1 
or neuropilin-1. Because VEGFR2 tran-
scription is dependent on the Sp1 tran-
scription factor, the researchers ana-
lyzed the effect of dimethylfumarate 
and demonstrated decreased binding 
of the Sp1 transcription factor to the 
VEGFR2 promoter. García-Caballero 
et al. (2011) also demonstrated inhi-
bition of tube formation on Matrigel 
by dimethylfumarate, but not by 
mono methylfumarate or free fumaric 
acid itself. They found that dimethyl-
fumarate does not inhibit the kinase 
activity of VEGFR2, and they demon-
strated antiangiogenic activity in two in 
vivo models: the quail chorioallantoic 
membrane and a transgenic zebrafish 
in which the endothelial cells are 
labeled with green fluorescent protein. 
Thus, it is safe to say that angiogenesis 
inhibition probably plays a role in the 
activity of dimethylfumarate.
One component to this question 
involves the decreased use of natural 
products as drugs or drug leads. The 
movement away from natural products 
probably reflects the complex synthet-
ic chemistry and medicinal chemistry 
requirements to optimize delivery and 
oral bioavailability and to minimize 
toxicity. Yet natural products tend to 
produce significant biological activ-
ity, presumably because nature has 
evolved three-dimensional configura-
tions that fit the “grooves and turns” of 
biochemically important molecules. 
In addition, many natural products 
are likely to target multiple species, 
thereby making the elucidation of their 
mechanism of action more challenging 
to dissect.
Although it is difficult to fully define 
mechanism, we know it when we see 
it. Mechanism is often presented as a 
crystal structure of a compound nestled 
in the crevices of a mutant protein, 
with hydrogen bonds of the target com-
pound closely approximating critical 
catalytic residues in the target protein. 
Polyphenols do not fit this conception 
of mechanism, because in most cases, 
including that of fisetin, we don’t even 
know the target protein. In fact, we don’t 
know whether it is a single target protein 
or multiple target proteins or whether 
the compounds inhibit protein–protein 
interactions. We do know that the com-
pound has downstream signaling activi-
ties that are important, such as upregu-
lation of E-cadherin and downregulation 
of c-myc and N-cadherin. Thus, efficacy 
in the absence of knowledge of precon-
ceived mechanism makes investigators 
uncomfortable, because it diminishes 
predictability. Apparently the same may 
be true of regulatory agencies, such as 
the Food and Drug Administration in 
the United States.
Better treatments for melanoma are 
possible, and they may be right around 
the corner. Perhaps a rejuvenated inter-
est in natural products would provide 
a boost—especially if combined with 
modern methods of target identification, 
pathway analysis, biomarker discovery, 
and combinatorial treatments. The 
power of nature’s tools is remarkable. 
Investigators understood this 40 years 
ago; revisiting the concept more vigor-
ously might benefit patients.
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Fumarate Esters as Angiogenesis 
Inhibitors: Key to Action in Psoriasis?
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Fumarate esters—an oral therapy for psoriasis—are used primarily in Europe, 
but not at all in the United States. Given that biological therapies are exceed-
ingly expensive and pose an increased risk for infections and malignancy, 
the need for safer and less expensive therapies for psoriasis is compelling. 
Nonbiological therapies for psoriasis, including methotrexate and system-
ic retinoids, carry potentially severe side effects and relatively high cost. 
Fumarate, a natural product that is generated internally in humans during 
the Krebs cycle, is an attractive alternative to these therapies. However, the 
mechanism for fumarate’s activity in psoriasis remains unknown.
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Several questions remain unan-
swered concerning the activity of 
fumarate esters. Although in vitro 
dimethylfumarate is more active than 
monoesters or fumaric acid itself, it is 
not known what percentage of dimeth-
ylfumarate passes through the diges-
tive tract and serum esterases to reach 
a psoriatic plaque. Thus, it is uncertain 
whether dimethylfumarate is the active 
metabolite in vivo. Second, deficiency 
of fumarate hydratase is associated 
with leiomyomas and renal cell car-
cinoma (Martinez-Mir et al., 2003; 
Pollard et al., 2007; Tomlinson et al., 
2002). Fumarate hydratase catalyzes 
the conversion of fumarate to malate 
in the Krebs cycle. Deficiencies of 
several Krebs cycle enzymes are asso-
ciated with both benign and malig-
nant neoplasms. Other enzymes that 
have been found to be associated with 
neoplasia include succinate dehydro-
genase and isocitrate dehydrogenase 
(IDH). In the case of IDH, an onco-
genic metabolite, 2-hydroxyglutarate 
has been proposed to account for 
the increase in tumors related to IDH 
deficiency, but in the case of fumarate 
hydratase and succinate dehydroge-
nase, the associated oncogenic metab-
olites are not known (Dang et al., 
2010). Critical to our understanding of 
carcinogenic mechanisms associated 
with Krebs cycle deficiencies is 
whether the defect is cell autonomous 
or nonautonomous and whether car-
cinogenesis is attributable to intra-
cellular metabolites of fumarate or 
high concentrations of extracellular 
fumarate. The lack of cancers, espe-
cially renal cell carcinoma, in patients 
taking dimethylfumarate for long 
periods suggests that high levels of 
extracellular fumarate do not mediate 
the carcinogenesis seen in fumarate 
hydratase deficiency.
Let us assume that fumarate is the 
active metabolite of dimethylfumarate. 
What is known about its mechan isms 
of action? Part of the proposed means 
of cancer pathogenesis, in the face of 
Krebs cycle deficiencies, is an upreg-
ulation of hypoxia-inducible factors 
(HIF1a and HIF2a) in the presence of 
normoxia (called “pseudohypoxia”) 
(Dang et al., 2010). The consequence 
of upregulating HIF is transcription-
al induction of vascular endothe-
lial growth factor (VEGF). Notably, 
although HIF1a and HIF2a are highly 
homologous, activation has differ-
ent consequences; in a study of renal 
cell carcinoma, the presence of HIF2a 
was found to be associated with an 
aggressive phenotype, whereas HIF1a 
overexpression is associated with a 
less aggressive phenotype, suggesting 
potential tumor suppressor activity 
of HIF1a (Gordan et al., 2008). In a 
murine model of fumarate hydratase 
deficiency, both HIF1a and HIF2a 
are induced as part of neoplasia. 
However, the addition of endogenous 
fumarate induces HIF1a but not HIF2a 
(MacKenzie et al., 2007). Thus, there 
is a difference between the effects of 
fumarate hydratase deficiency and 
large quantities of exogenous fumarate 
(Yogev et al., 2010). The most likely 
model to explain fumarate’s beneficial 
activity is through induction of HIF1a 
(Figure 1), leading to downregulation 
of NF-kB and Sp1; precedence for an 
anti-inflammatory effect of HIF1a has 
been demonstrated through induction 
of heme oxygenase-1 (Belcher et al., 
2006; Chin et al., 2007).
Fumarate has been useful in treat-
ing psoriasis, and there is reason to 
believe it may be effective in treating 
other inflammatory disorders. It is for-
tunate that fumarate has already been 
approved for human use, because in 
today’s regulatory climate it would 
likely not be approved, especially as 
a nontargeted therapy. Further stud-
ies of fumarate esters’ mechanism of 
action are warranted because they 
could lead to safe and effective sys-
temic therapies for psoriasis and other 
inflammatory disorders.
Figure 1. Proposed mechanisms of action for extracellular and intracellular fumarate. Extracellular 
fumarate may cause an induction of hypoxia inducible factor (HIF) 1a but downregulation of HIF2a. 
Anti-inflammatory effects of HIF1a induction may be mediated through downregulation of NF-kB and 
upregulation of heme oxygenase 1. In renal collecting duct cells, fumarate hydratase deficiency may 
lead to upregulation of both HIF1a and HIF2a through a reactive oxygen–dependent pathway. ICAM, 
intercellular cell adhesion molecule; VCAM, vascular cell adhesion molecule; VEGFR2, vascular 
endothelial growth factor receptor.
Clinical Implications
•  Fumarate esters, which inhibit angiogenesis, are effective in treating 
psoriasis.
•  Fumarate esters, as intermediary compounds in the Krebs cycle, are less 
like to cause toxicity.
•  Fumarate esters are proposed as relatively safe, effective drugs for 
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